Cliff Asness’s Cartesian Therapeutics RNAC Stock Holding History

Cliff Asness’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71M	Buy	356,456 +272,436	+324%	+$2.02M	﹤0.01%	2197
2026 Q1	$517K	Buy	+84,020	New	+$599K	﹤0.01%	3104
2022 Q3	–	Sell	-42,932	Closed	-$1.69M	–	2302
2022 Q2	$1.69M	Buy	42,932 +24,384	+131%	+$723K	﹤0.01%	1181
2022 Q1	$684K	Buy	18,548 +834	+5%	+$52.2K	﹤0.01%	1697
2021 Q4	$1.73M	Buy	17,714 +4,569	+35%	+$492K	﹤0.01%	1260
2021 Q3	$1.64M	Buy	13,145 +1,792	+16%	+$216K	﹤0.01%	1267
2021 Q2	$1.42M	Sell	11,353 -2,521	-18%	-$300K	﹤0.01%	1411
2021 Q1	$1.88M	Buy	13,874 +286	+2%	+$35.5K	﹤0.01%	1236
2020 Q4	$1.24M	Buy	13,588 +3,600	+36%	+$312K	﹤0.01%	1405
2020 Q3	$743K	Buy	+9,988	New	+$765K	﹤0.01%	1563
2019 Q2	–	Sell	-7,092	Closed	-$504K	–	2167
2019 Q1	$504K	Buy	+7,092	New	+$449K	﹤0.01%	1805

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cliff Asness's RNAC Position: Q2 2026 in Review

Cliff Asness increased its Cartesian Therapeutics (RNAC) stake by 324% in Q2 2026, buying an estimated $2.02M and bringing the position to 356,456 shares worth $3.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

Cliff Asness first reported a position in RNAC in Q1 2019 and has held it in 11 quarters since. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Cliff Asness held 356,456 shares of Cartesian Therapeutics worth $3.71M as of Q2 2026.
Cliff Asness bought 272,436 Cartesian Therapeutics shares in Q2 2026, an estimated $2.02M.
Cartesian Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2197 holding.
Cliff Asness first reported a position in Cartesian Therapeutics in Q1 2019 and has held it in 11 quarters since.
94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.